Immunoscintigraphy with 131I-labelled monoclonal antibodies HMFG2 and HMFG1 F(ab')2 versus abdominal CT scan in the detection of residual disease in ovarian cancer patients

✍ Scribed by D. Pectasides; K. Pateniotis; L. Tzimis; X. Trapalli; P. Natsis; P. Arapantoni; J. Taylor-Papadimitriou; A. Epenetos; P. Koutsiouba; A. Athanassiou

• Publisher: John Wiley and Sons
• Year: 1988
• Tongue: French
• Weight: 514 KB
• Volume: 41
• Category: Article
• ISSN: 0020-7136
• DOI: 10.1002/ijc.2910410817

✦ Synopsis

3'I-labelled HMFGl or HMFGl F(ab')2 monoclonal antibody (MAb) was administered intraperitoneally to I S patients with epithelial ovarian cancer who had completed chemotherapy and were in complete or good partial remission. Each patient received 2-3 mCi. Patients were scanned immediately after and until 7 days post-injection. In 3/15 patients the immunoscan failed because extensive adhesions from the previous surgery prevented MAb diffusion. Of the remaining 12 patients, 9 underwent second-look laparotomy (SL). lmmunoscan was true positive in 8/9 (89Oh) patients and equivocal in 1/9 (I I %), whereas the abdominal CT scan gave true positive results in 6/9 (67%) patients. In 8 out of 9 patients there was a good correlation between distribution of all sites of abnormal uptake and the surgical findings at SL. Of the 3 patients not undergoing SL, the immunoscan was positive in all, whereas clinical examination and abdominal CT scan were negative. All 3 patients relapsed after 3, 4 and 5 months. Thus the total true positivity of immunoscan reached 92%. CT scan remaining at 50%. lmmunoscan with intraperitoneal administration of '"I-labelled MAbs can thus accurately detect the presence of residual disease in ovarian cancer patients and appears more sensitive than abdominal CT scan.